After a successful congress, in which many of Europe's leading veterinarians in oncology participated, we can announce that our TSE™ technology and vetIQure™ created a lot of attention.

We would like to thank the organisers of ESVONC and the veterinarians from Evidensia and AniCura who actively helped us make connections within their respective organisations.

A special thank you goes to veterinarian Majbritt M.E Larsen, Specialist in small animal internal medicine and head of Oncology at Evidensia Specialistdjursjukhuset Helsingborg, for our collaboration which, among other things, has resulted in the poster that was published at the congress.

Link to the press release where the poster is also published (https://news.cision.com/chemotech/r/scandinavian-chemotech-s-tse-technology-gives-hope-to-horses-suffering-from-sarcoids,c3574986)

"It has been an intense weekend in Italy where we met the market for the first time and where the old static electroporation was also exhibited. It feels like our analysis of the market and the potential for TSE in veterinary medicine has been completely correct. The interest in a less destructive method that is gentler and that reduces the risks of necrosis and inflammation is very big. It is now important that we continue our focus and create both commercial and clinical success from all the expressions of interest we received." - says Mohan Frick, CEO of ChemoTech